
Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become increasingly popular over the past decade for the treatment of type 2 diabetes and obesity, with versions like Ozempic and Wegovy becoming household names.